Genscript Biotech Corporation
金斯瑞生物科技股份有限公司 *
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1548)

VOLUNTARY ANNOUNCEMENT
RESEARCH AND DEVELOPMENT UPDATE

Reference is made to the voluntary announcements of GenScript Biotech Corporation (the "**Company**", together with its subsidiaries, the "**Group**") dated 4 April 2019, 6 December 2020, 21 December 2020, 13 January 2021 and 1 February 2021.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that, on 30 April 2021 (New York time), Legend Biotech Corporation ("**Legend Biotech**"), a non-wholly owned subsidiary of the Company, announced the submission of a Marketing Authorisation Application (the "**MAA**") to the European Medicines Agency (the "**EMA**") seeking approval of ciltacabtagene autoleucel (cilta-cel) for the treatment of patients with relapsed and/or refractory multiple myeloma (the "**Submission**").

Cilta-cel is an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy being investigated as a treatment for multiple myeloma. The MAA is based on positive results from a Phase 1b/2 CARTITUDE-1 study, which were presented at the American Society of Hematology (ASH) 2020 Annual Meeting. The Submission was filed to the EMA by Janssen-Cilag International N.V., an affiliate of Janssen Biotech, Inc. ("**Janssen**"), Legend's collaboration partner for cilta-cel. For details of the presentation, please refer to the announcement of the Company dated 6 December 2020.

The Submission is a testimony to the promising results the Group has seen from the CARTITUDE-1 study showing the efficacy and safety of cilta-cel for treating patients with multiple myeloma who are heavily pretreated and in need of treatment options. The Group is proud of its collaboration with Janssen and looks forward to bringing this personalized treatment to patients in the European Union following the accelerated assessment.

The EMA's Committee for Medicinal Products for Human Use (CHMP) granted accelerated assessment for the MAA. An accelerated assessment is granted when the CHMP determines that a medicinal product is of major public health interest and therapeutic innovation and can significantly reduce the review timelines to evaluate an MAA. Cilta-cel previously received a PRIority MEdicines (PRIME) designation from the EMA. A Biologics License Application (BLA) seeking approval of cilta-cel based on the CARTITUDE-1 study is currently under review with the United States Food and Drug Administration (FDA).

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By Order of the Board
Genscript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Hong Kong, 30 April 2021

As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.

* *For identification purposes only*